Bispecific antibodies are an emerging class of drugs in breast cancer clinical research. By binding to two distinct targets, a bispecific antibody can do two jobs and may work better than traditional antibody drugs.
Several bispecific antibodies are being studied in trials for MBC. For example, the bispecific antibody zanidatamab binds to two targets on the HER2 receptor in HER2+ MBC. Other bispecific antibodies, such as KN046, bring immune cells and tumor cells together to kill tumor cells in triple-negative MBC.
Read below for general information about how bispecific antibodies work in cancer and specifically how they work in MBC.
General Information About Bispecific Antibodies
- Dana-Farber Cancer Institute: Bispecific Antibodies: How Can They Treat Cancer?
Information On MBC Bispecific Antibodies
- OncLive: Bispecific Antibodies Like Zanidatamab Have Promise in Heavily Pretreated HER2+ Breast Cancer
- Practice Update: KN026 for HER2-Positive MBC
- AACR Abstract: KN046 for Triple-Negative MBC
Clinical Trials That Include Bispecific Antibodies
- Metastatic Trial Search: MBC Trials That Include Bispecific Antibodies
- Solid Tumor Trials: Trials That May Include Bispecific Antibodies
Tags:HER2Antibody Drug ConjugatesTNBCResearch NewsTargeted Therapy